Search Results

Data published in Molecular Therapy – Methods and Clinical Development confirm the potential preclinical benefit of the sa-mRNA technology platform, the next generation of mRNA vaccine technology

https://www.cslseqirus.us/news/csl-announces-positive-preclinical-data-for-self-amplifying-messenger-rna-flu-vaccine-candidates

CSL Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.

https://www.cslseqirus.us/products

New data from four real-world studies shows the impact that cell-based and adjuvanted influenza vaccines can have in reducing the burden of seasonal influenza on hospitals and health systems.

https://www.cslseqirus.us/news/new-rwd-presented-options-xi-show-influenza-vaccines-can-reduce-burden-of-seasonal-influenza

Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.

https://www.cslseqirus.us/expertise/influenza

CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.cslseqirus.us/expertise

This year marks the first full season that Seqirus’ portfolio of innovative influenza vaccines provides a differentiated vaccine option for people of all ages who are eligible in the U.S. to receive a flu shot

https://www.cslseqirus.us/news/seqirus-begins-shipping-portfolio-of-innovative-influenza-vaccines-for-the-2022-23-us-season

CSL Seqirus will manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. government’s pandemic preparedness activities

https://www.cslseqirus.us/news/csl-seqirus-us-government-award-to-manufacture-and-assess-influenza-a-h5n8-pre-pandemic-vaccine

CSL Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.cslseqirus.us/expertise/influenza/pandemic-response-solutions

CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens

https://www.cslseqirus.us/news/csl-announces-closing-of-global-collaboration-and-licensing-agreement-with-arcturus-therapeutics

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.cslseqirus.us/news